An interventional study of a combined regimen consisting of double-dose third-generation EGFR-TKI, bevacizumab, and intrathecal chemotherapy in patients in Leptomeningeal Metastasis and Lung Neoplasms, Non-Small Cell Lung Cancer, sponsored by Second Affiliated Hospital of Nanchang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Second Affiliated Hospital of Nanchang University · Not applicable, Interventional, and Treatment
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Meningeal Carcinomatosis with a site in China — 29 open to participants now, 34 under way, none of them phase 3. Meningeal Carcinomatosis · China.
Among the 54 studies in Meningeal Carcinomatosis with a site in China, this one is the 33rd largest by planned enrollment of the 46 interventional ones that give a count, is one of 8 that started in 2026, is one of 10 with no phase, reaches primary completion later than 21 of the 33 other live ones, and was the 51st registered.
146 studies on the registry are indexed under Meningeal Carcinomatosis; 48 are open to participants now.
Browse Meningeal Carcinomatosis studies →29 of the 54 studies in Meningeal Carcinomatosis with a site in China are open now. Recruiting first, the newest first:
Guangzhou University of Traditional Chinese Medicine · Sites in China
Ages 18–75
Alpha Biopharma (Jiangsu) Co., Ltd. · Sites in China
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
Guangzhou Medical University · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 33 Meningeal Carcinomatosis studies recruiting now, 21 (64%) set no upper age limit and 10 (30%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 27 · Phase 4 3
First in 2011; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is close to the median of 30 across 128 interventional studies indexed under Meningeal Carcinomatosis.
Median enrollment 39 across the 46 interventional studies, 86 across the 8 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 54 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital of Nanchang University is the lead sponsor of 85 studies on the registry; 52 are open to participants now.
Second Affiliated Hospital of Nanchang University has 4 studies filed under Meningeal Carcinomatosis — fewer than ten, so there is no comparison to draw.
10 of the studies in Meningeal Carcinomatosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06462222Guangzhou Medical UniversityImmune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors | 2026-11 |
| NCT06809530Guangzhou Medical UniversityIntrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis | 2026-12-01 |
| NCT06462092Guangzhou Medical UniversitySacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer | 2027-01-15 |
| NCT07193654Second Affiliated Hospital, School of Medicine, Zhejiang UniversityStupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread | 2027-04-01 |
| NCT07092202Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyFirmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases | 2027-05-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 54 studies in Meningeal Carcinomatosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to explore the efficacy and safety of double-dose third-generation EGFR-TKI combined with bevacizumab and intrathecal chemotherapy in treating advanced non-small cell lung cancer (NSCLC) patients with leptomeningeal metastasis that progressed after prior standard-dose third-generation EGFR-TKI treatment. It also aims to investigate the correlation between cerebrospinal fluid genetic characteristics and prognosis as well as subsequent efficacy prediction in patients with leptomeningeal metastasis after resistance to standard-dose third-generation EGFR-TKI. The main questions it intends to answer are:
Does this combined treatment regimen improve leptomeningeal metastasis response rate (LM-ORR) evaluated by RANO-LM? What adverse events occur in patients during the treatment with this combined regimen? Researchers will conduct a single-arm phase II prospective study to assess the effectiveness and safety of the combined treatment, without a control group comparison.
Participants will:
Receive double-dose third-generation EGFR-TKI (osimertinib 160mg qd, furmonertinib 160mg qd, or almonertinib 220mg qd) + intrathecal pemetrexed (induction phase: 10mg twice a week for 4 weeks; maintenance phase: 10mg once a week for 4 weeks; consolidation phase: 30mg every 4 weeks until disease progression or intolerable toxicity) + bevacizumab 7.5mg/kg.
Undergo screening assessments within 28 days before enrollment, including tumor imaging, laboratory tests, and cerebrospinal fluid examination.
During the treatment period, conduct regular checkups and tests (such as blood routine, blood biochemistry, electrocardiogram, and imaging examinations) according to the protocol (once every 4 weeks in the first two treatment cycles, then once every 8 weeks).
Complete quality of life assessment using the QLQ-C30 scale every 4 weeks and record changes in neurological symptoms and ECOG scores.
Study Population 2.1 Inclusion Criteria Participants must meet all the following criteria to be enrolled: aged ≥18 years at the time of signing the informed consent form, regardless of gender; histologically or cytologically confirmed advanced or metastatic NSCLC, staged as IV according to the 8th edition of the IASLC TNM classification (2015); presence of EGFR-sensitive mutations (exon 19 deletion or exon 21 mutation), with LM progression after prior standard-dose third-generation EGFR-TKI treatment (allowed treatment sequences: 1st+3rd generation, 2nd+3rd generation, or direct 3rd generation), no restriction on the number of prior chemotherapy lines, and stable parenchymal brain and extracranial lesions; ECOG Performance Status (PS) score of 0-3; normal major organ function, including hemoglobin (Hb) ≥90g/L, absolute neutrophil count (ANC) ≥1.5×10⁹/L, platelet (PLT) ≥100×10⁹/L, white blood cell count (WBC) ≥3.0×10⁹/L (without blood transfusion or hematopoietic stimulants within 14 days), alanine transaminase (ALT) and aspartate transaminase (AST) ≤2.5×upper limit of normal (ULN), total bilirubin (TBIL) ≤1.5×ULN, serum creatinine (Cr) ≤1.5×ULN or creatinine clearance ≥50ml/min (for patients with liver metastasis: TBIL ≤3×ULN, ALT and AST ≤5×ULN), activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT) ≤1.5×ULN, and left ventricular ejection fraction (LVEF) ≥50% by Doppler ultrasound; compliance with washout period requirements (≥21 days since the last chemotherapy dose if no prior radiotherapy, ≥14 days since the end of local radiotherapy for parenchymal brain metastases, ≥30 days since surgical resection of parenchymal brain metastases with full recovery from acute toxicity); expected survival time ≥3 months; ability to swallow oral medications (or receive crushed medications via gastrostomy tube if unable to swallow); for women of childbearing age, negative pregnancy test (serum or urine) within 14 days before enrollment and agreement to use effective contraception during the study and for 3 months after the last study drug administration; for men, surgical sterilization or agreement to use effective contraception during the same period; voluntary participation, signed informed consent (or by legal representative), and good expected compliance with study procedures.
2.2 Exclusion Criteria Participants will be excluded if they meet any of the following: major surgery within 4 weeks before the start of study treatment or planned surgery during the study; human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); active bacterial or fungal infections requiring intravenous antibiotics at the start of study treatment; history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid treatment, or signs of clinically active interstitial lung disease; arterial/venous thromboembolic events within 6 months before enrollment (including cerebrovascular accident, deep vein thrombosis, or pulmonary embolism); significant cardiovascular disease history (New York Heart Association class >2 congestive heart failure, unstable angina, myocardial infarction within 3 months before signing the informed consent form, symptomatic arrhythmias requiring treatment, or mean corrected QT interval (QTcF) >470ms on 3 consecutive electrocardiograms); history of other systemic malignant tumors within 5 years (excluding cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and ovarian cancer); use of drugs or supplements known to be strong inducers of CYP3A4; known allergy to any study drug or its excipients; pregnancy, lactation, or refusal of effective contraception by patients of childbearing potential; history of definite neurological or psychiatric disorders (including epilepsy and dementia); other conditions deemed unsuitable for enrollment by the investigator.
Study Design and Treatment Regimen 3.1 Study Design This is an open-label, single-arm Phase II prospective study with no randomization or blinding. The planned sample size is 30 patients, calculated based on a Pearson chi-square test to detect an increase in clinical response rate from 40% to 80% (power=0.8, one-sided significance level=0.20, 10% dropout rate).
3.2 Treatment Regimen The combined treatment includes three components: double-dose third-generation EGFR-TKI (oral osimertinib 160mg once daily, furmonertinib 160mg once daily, or almonertinib 220mg once daily); intrathecal pemetrexed (administered via lumbar puncture, Ommaya reservoir, or intrathecal pump, with induction phase: 10mg twice weekly for 4 weeks, maintenance phase: 10mg once weekly for 4 weeks, consolidation phase: 30mg every 4 weeks until disease progression or intolerable toxicity); and bevacizumab 7.5mg/kg administered intravenously.
3.3 Dose Adjustment and Management For missed doses: if vomiting occurs shortly after drug administration, no re-dose is given; for missed doses within 2 hours of the scheduled time, the dose is supplemented, otherwise, it is skipped without cycle adjustment. For intrathecal pemetrexed, administration requires ANC ≥1.5×10⁹/L, PLT ≥75×10⁹/L, Hb ≥80g/L, and ≤Grade 2 fatigue, oral mucositis, or neurotoxicity; for Grade ≥3 hematological or non-hematological toxicity, the next dose is reduced by 10mg. For bevacizumab, Grade 3-4 related adverse events (AEs) require treatment suspension until recovery to ≤Grade 1, then resumption at the original dose; permanent discontinuation is considered if toxicity fails to resolve or poses ongoing risks.
Study Procedures 4.1 Screening Period (D-28 to D-1) Within 28 days before enrollment, participants complete informed consent signing, collection of demographic and medical history data, tumor imaging (chest/abdominal/pelvic CT/MRI within 4 weeks), echocardiogram, drug allergy history review, and concurrent medication documentation. Within 14 days before drug administration, additional assessments include ECOG PS scoring, physical examination, laboratory tests (blood routine, urine routine, blood biochemistry, stool occult blood, coagulation function), electrocardiogram, pregnancy test, myocardial enzyme profile, HIV/hepatic B/hepatic C screening, thyroid function test, and CSF examination. Eligibility is confirmed only after all inclusion and exclusion criteria are met.
4.2 Treatment Period In Cycle 1 (Month 1), assessments include vital signs, physical examination, AE monitoring, concurrent medication recording, and drug administration on Day 1; ECOG PS scoring, laboratory tests, electrocardiogram, and AE monitoring on Day 14; and imaging assessment on Day 28. For Cycle 3 and beyond, Day 1 assessments are the same as Day 14 of Cycle 1, Day 14 includes ECOG PS scoring, vital signs, physical examination, and AE monitoring, and imaging assessment is performed on Day 56. Imaging assessment frequency is every 4 weeks for the first 2 cycles, then every 8 weeks, and every 12 weeks after 1 year of follow-up. Extracranial lesions are evaluated per RECIST v1.1, and intracranial lesions per RANO-LM criteria.
4.3 Follow-up Period Safety follow-up is conducted 30 days after the last study drug administration, repeating the assessments performed at treatment termination. Survival follow-up occurs every 3 months ±14 days to collect survival status and subsequent treatment information, with imaging assessments as per the treatment period schedule until new anticancer treatment initiation or disease progression.
Study Endpoints 5.1 Primary Endpoint The primary endpoint is leptomeningeal metastasis overall response rate (LM-ORR) evaluated by RANO-LM criteria.
5.2 Secondary Endpoints Secondary endpoints include quality of life (QoL) assessed by the QLQ-C30 scale; leptomeningeal metastasis progression-free survival (LM-PFS), defined as the time from treatment initiation to LM progression or death; overall survival (OS), defined as the time from treatment initiation to death or last follow-up; improvement and duration of neurological symptoms/signs (from the date of significant/partial improvement to deterioration due to LM progression); improvement and duration of ECOG PS (from the date of ECOG score improvement to deterioration due to LM progression); and safety profile.
5.3 Exploratory Endpoint The exploratory endpoint is the correlation between CSF genetic characteristics and prognosis/efficacy prediction in patients with LM following resistance to standard-dose third-generation EGFR-TKI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination Product: a combined regimen consisting of double-dose third-generation EGFR-TKI, bevacizumab, and intrathecal chemotherapy in patients
The combined treatment includes three components: double-dose third-generation EGFR-TKI (oral osimertinib 160mg once daily, furmonertinib 160mg once daily, or almonertinib 220mg once daily); intrathecal pemetrexed (administered via lumbar puncture, Ommaya reservoir, or intrathecal pump, with induction phase: 10mg twice weekly for 4 weeks, maintenance phase: 10mg once weekly for 4 weeks, consolidation phase: 30mg every 4 weeks until disease progression or intolerable toxicity); and bevacizumab 7.5mg/kg administered intravenously.
This study also gives OsimertinibStudies of OsimertinibOsimertinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
LM-ORR
The primary endpoint is leptomeningeal metastasis overall response rate (LM-ORR) evaluated by RANO-LM criteria.
Time frame: Up to 30 days after the last study drug administration (for safety and response assessment), and through study completion, an average of 1 years (for survival follow-up)
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osimertinib
Second Affiliated Hospital of Nanchang University